JK Agri Genetics to Review September Quarter Results Today

JK Agri Genetics Ltd will consider unaudited financial results for the quarter and half year ended September 30, 2026, at its board meeting on October 30. The review follows a June-quarter performance in which standalone sales fell 8.27% year on year to ₹84.33 crore and net profit declined 11.48% to ₹10.87 crore.

What will JK Agri Genetics consider at the October 30 board meeting?

JK Agri Genetics will consider and approve its unaudited financial results for the second quarter and first half of FY2026-27 at a board meeting scheduled for Friday, October 30, 2026. The company disclosed that the meeting concerns the period ended September 30, 2026.

The intimation states that the meeting is being held in compliance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The provided information does not include the September-quarter financial figures, management commentary, or a date for any further business decisions by the board.

The scheduled results matter because they will provide the first official update after the June 2026 quarter. They will also show the combined financial position for the April-September half year, including the seasonal movement in sales and profitability recorded by the company.

How did JK Agri Genetics perform in the June 2026 quarter?

JK Agri Genetics reported standalone net sales of ₹84.33 crore for the quarter ended June 2026, compared with ₹91.93 crore in the corresponding quarter of the previous year. The 8.27% year-on-year decline came alongside a fall in net profit to ₹10.87 crore from ₹12.28 crore, a decrease of 11.48%.

The company reported an operating profit margin of 18.00% for the June 2026 quarter, versus 19.37% a year earlier. Profit before depreciation and tax was ₹15.93 crore, down from ₹18.90 crore, while profit before tax declined to ₹15.30 crore from ₹17.72 crore.

The June-quarter report therefore showed lower sales as well as a lower operating margin compared with the prior-year period. Although the company remained profitable during the quarter, the reported reduction in both revenue and net profit establishes the immediate financial context for the September-quarter review.

What do the March 2026 results show about JK Agri Genetics?

JK Agri Genetics reported standalone sales of ₹22.96 crore for the March 2026 quarter, down 16.78% from ₹27.59 crore in the March 2025 quarter. It recorded a net loss of ₹9.10 crore, compared with a loss of ₹1.35 crore in the corresponding period a year earlier.

The March-quarter operating result was also negative. EBITDA stood at a negative ₹0.50 crore, compared with a positive ₹1.23 crore in the prior-year quarter. On the consolidated basis, the supplied figures show sales of ₹22.96 crore and a net loss of ₹9.09 crore for the same quarter.

For the full year ended March 2026, the company reported sales of ₹157.59 crore, down 2.60% from ₹161.79 crore in the year ended March 2025. Its full-year net loss widened to ₹7.17 crore from ₹2.50 crore in the prior year.

Why are the September-quarter results important for investors?

The September-quarter results are important because they will indicate whether the sales decline reported in June continued into the next quarter. They will also provide the half-year figures, allowing investors to assess the June-quarter profit against the company’s performance across the first six months of FY2026-27.

The recent reporting pattern has varied substantially by quarter. JK Agri Genetics recorded a profit of ₹10.87 crore in the June 2026 quarter after reporting a loss of ₹9.10 crore in the March 2026 quarter. The supplied quarterly profit and loss series also lists losses of ₹5.27 crore in December 2025 and ₹5.09 crore in September 2025, while the June 2025 quarter showed a profit of ₹12.28 crore.

This variation makes the company’s upcoming disclosure relevant for shareholders tracking revenue, operating margins and profit or loss. The board meeting notice, however, does not provide guidance on expected sales, margins, earnings, or future business conditions. Any assessment of the September quarter will depend on the unaudited results released after board approval.

How does the update affect JK Agri Genetics' market context?

The immediate market relevance of the announcement is disclosure-related rather than a reported new financial outcome. JK Agri Genetics has formally notified investors that its board will review the September-quarter and half-year results, which sets the next point for updated financial information.

The June results showed that sales were lower than the comparable prior-year quarter and that net profit also declined. The March results and the full-year FY2025-26 figures showed losses, including a widened annual net loss. Together, these disclosed figures give investors a factual basis to compare the forthcoming half-year data with recent quarterly and annual performance.

The supplied material does not state a share-price movement, analyst recommendation, production change, customer impact, or management explanation for the changes in sales and profit. It also does not identify any new policy, capital expenditure plan, or operational target linked to the October 30 meeting.

Conclusion

JK Agri Genetics is scheduled to review its unaudited September 2026 quarter and half-year results on October 30. The disclosure follows a June quarter in which standalone sales fell to ₹84.33 crore and net profit declined to ₹10.87 crore, after a loss-making March quarter and a full year that ended with a net loss of ₹7.17 crore.

The next item to watch is the board-approved September-quarter release, particularly its reported sales, operating margin, net profit or loss, and first-half figures. The company’s meeting intimation identifies the results review but does not disclose earnings guidance or any operational target beyond the scheduled approval process.